Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

New study points the way for improved anaemia management in dialysis patients

Roche Pharmaceuticals : 19 October, 2007  (New Product)
Dialysis patients can be switched effectively from frequently dosed anaemia drugs to an innovative investigational anaemia treatment, Mircera, administered up to once every four weeks. That is the conclusion of a pivotal study published in The Lancet.
The MAXIMA study is the first randomised, comparative study to investigate the direct conversion of dialysis patients with chronic kidney disease from treatment with erythropoiesis-stimulating agents (ESA) given one to three times a week to IV Mircera administered once every two weeks or once every four weeks.

The results demonstrated that Mircera maintained haemoglobin (Hb) concentrations within the target range as effectively as ESAs epoetin alfa or beta, which are typically given three times a week.

'Our findings demonstrate that Mircera was administered up to once every four weeks in haemodialysis patients without sacrificing haemoglobin stability,' said Nathan Levin, MD, Medical and Research Director, Renal Research Institute, New York, New York, and the lead author of the publication. 'We note in The Lancet that these results should be generalisable to the maintenance haemodialysis population and that we believe this drug should be an option to epoetin for simplified anaemia management.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo